Norwegian officials confirmed on Thursday that a second person and another man had died in Sweden from severe thromboembolic complications after receiving the Astrogenega vaccine against Kovit-19.
Norway recorded a total of six cases with an abnormal clinical picture involving low platelet counts, blood clotting and bleeding, as found in many countries.
A team of doctors at Oslo University Hospital announced a few hours ago that the immune reaction to the AstraZeneca vaccine was due to thrombosis experienced by three health professionals admitted to the hospital at the site over the weekend, one of whom died last Sunday.
“We have made a number of discoveries that could explain the clinical evolution of patients. These findings support our hypothesis that they have a strong immune response that leads to the formation of antibodies, which in turn activate platelets and cause thrombi,” said Paul Andre Home. Chairman of the Medical Committee.
The European Medicines Agency (EMA) today finds no evidence that it is directly related to cases of thromboembolism found across the continent and considers it safe to use, although the possibility of resolving a link is not entirely out there.
Many countries, such as Italy or Spain, have reaffirmed their vaccination with AstraZeneca. But Norway will continue to study episodes recorded in this country.
“We are exploring in detail if there is a link between vaccination cases. We will study the analysis of the EMA and report it to us next weekend,” said Camila Stoltenberg, director of the Public Health Agency.
Denmark, the first country to discontinue the use of the astrogenic vaccine a week ago, maintains this decision.
The Danish pharmaceutical company said today that a total of ten cases of thrombosis have been reported after receiving the vaccine, although it has not yet been determined whether there is a link.
Danish authorities announced the death of a woman under the age of 60 a few days ago with a rare medical picture.
The Swedish Medicines Agency today confirmed the death of another woman in her 60s and without previous illnesses, with a similar medical picture and another case under suspicion.
Sweden, one of the last countries to join the suspension of AstraZeneca, said the decision would be maintained for some time.
“The public health agency needs a few days to study the situation of how the vaccine can be used in Sweden,” said its director Johann Carlson.